Appointments at Cadence Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Cadence Pharmaceuticals (US) has appointed Dr Todd Rich to the company's board of directors and named Malcolm Lloyd-Smith senior vice-president of regulatory affairs and quality assurance. Mr Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company; he was previously vice-president and head of global regulatory affairs at Elan Pharmaceuticals. Dr Rich is vice-president of development regulatory, medical information, drug safety, quality and compliance at Genentech.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.